OmniSeq’s vision is to provide the right drug or right trial…for every patient.
Founded in 2015, OmniSeq’s mission is to deliver superior results by improving access to better cancer treatment options through comprehensive molecular profiling. OmniSeq is a commercial, CLIA and NYS CLEP licensed clinical laboratory in Buffalo, New York. The company utilizes next generation DNA sequencing (NGS) technologies through NYS CLEP approved comprehensive molecular profiling. OmniSeq also offers a wide variety of Pharmaceutical services to assist in drug development.
OmniSeq is a subsidiary of Roswell Park Cancer Institute (RPCI), which was the first institution to focus exclusively on cancer research and continues to be at the center of groundbreaking cancer research for more than a century. This includes becoming America’s first comprehensive cancer center, an NCI designation they currently maintain. The breakthrough research, scientific expertise, and commitment to improving patient care instilled at RPCI is the foundation of OmniSeq today.